ev-103: ev pembrolizumab as a promising first-line option for urothelial carcinoma
Published 10 months ago • 170 plays • Length 6:02Download video MP4
Download video MP3
Similar videos
-
2:43
ev-103: ev with pembrolizumab in cisplatin-ineligible urothelial carcinoma
-
2:10
initial ev-103 results: enfortumab vedotin plus pembrolizumab for urothelial carcinoma
-
13:47
ev-103: enfortumab vedotin and pembrolizumab in urothelial carcinoma
-
2:20
ev-103 cohort k: enfortumab vedotin /- pembro in untreated cis-ineligible patients with muc
-
1:02
the role of ev and pembrolizumab in the urothelial carcinoma treatment landscape
-
0:35
ev-302: 1l enfortumab vedotin in combination with pembrolizumab
-
3:24
enfortumab vedotin as treatment for urothelial carcinomas
-
3:07
enfortumab vedotin in urothelial cancer
-
0:34
pembrolizumab plus enfortumab vedotin for bladder cancer
-
0:45
prof. siefker-radtke on the ev-103 trial in bladder cancer
-
2:58
ev-201: enfortumab vedotin for cisplatin-ineligible bladder cancer
-
2:41
firstline pembrolizumab for metastatic urothelial cancer
-
0:49
evolving landscape of urothelial cancer treatment: erdafitinib or enfortumab vedotin?
-
3:25
enfortumab vedotin with pembrolizumab for bladder cancer
-
2:20
ev-201: enfortumab vedotin for bladder cancer
-
2:09
ev-103: neoadjuvant enfortumab vedotin in cis-ineligible mibc
-
1:29:54
examining the state of the science on new therapies in bladder cancer
-
1:07
dr. petrylak on the results of the ev-103 trial in bladder cancer
-
0:50
enfortumab vedotin appears well-tolerated and active in advanced bladder cancers